Papp Mariusz, Gruca Piotr, Lason-Tyburkiewicz Magdalena, Willner Paul
aInstitute of Pharmacology, Polish Academy of Sciences, Krakow, Poland bDepartment of Psychology, Swansea University, Swansea, UK.
Behav Pharmacol. 2017 Feb;28(1):1-8. doi: 10.1097/FBP.0000000000000259.
Ketamine is the prototype of a new generation of antidepressant drugs, which is reported in clinical studies to be effective in treatment-resistant patients, with an effect that appears within hours and lasts for a few days. Chronic mild stress (CMS) is a well-established and widely used animal model of depression, in which anhedonia, anxiogenesis and cognitive dysfunction can be observed reliably. Studies using acute or brief ketamine treatment following withdrawal from CMS have replicated the clinical finding of a rapid onset of antidepressant action. However, there have been no CMS studies of chronic daily ketamine treatment or continued stress following ketamine treatment, which would have greater translational potential in relation to the long-term maintenance of antidepressant effects. Wistar rats were drug treated following an initial 2 weeks of CMS exposure, which continued alongside daily drug treatment. A first experiment tested a range of chronic (5 weeks) ketamine doses (5-30 mg/kg); a second compared the effects of subacute (3-5 days) and chronic (5 weeks) treatment. CMS-induced anhedonic, anxiogenic and dyscognitive effects, as measured, respectively, by decreased sucrose intake, avoidance of open arms in the elevated plus maze and loss of discrimination in the novel object recognition test. A sustained antidepressant-like effect of ketamine in the sucrose intake test was observed in both experiments, with an onset at around 1 week, faster than imipramine, and an optimum dose of 10 mg/kg. Anxiogenic and dyscognitive effects of CMS, in the elevated plus maze and novel object recognition test, respectively, were fully reversed by both subacute and chronic ketamine treatment. Daily treatment with ketamine in the CMS model causes sustained long-term antidepressant, anxiolytic and procognitive effects. The demonstration of a procognitive effect of ketamine may have particular translational value.
氯胺酮是新一代抗抑郁药物的原型,临床研究报告称其对难治性患者有效,用药后数小时内起效,药效可持续数天。慢性轻度应激(CMS)是一种成熟且广泛应用的抑郁症动物模型,在此模型中可可靠地观察到快感缺失、焦虑症和认知功能障碍。对从CMS模型撤药后使用急性或短期氯胺酮治疗的研究,重现了抗抑郁作用起效迅速这一临床发现。然而,尚无关于氯胺酮每日慢性治疗或氯胺酮治疗后持续应激的CMS研究,而这类研究对于抗抑郁效果的长期维持可能具有更大的转化潜力。Wistar大鼠在最初暴露于CMS 2周后接受药物治疗,且在每日药物治疗期间CMS持续存在。第一个实验测试了一系列慢性(5周)氯胺酮剂量(5 - 30毫克/千克);第二个实验比较了亚急性(3 - 5天)和慢性(5周)治疗的效果。通过蔗糖摄入量减少、高架十字迷宫中对开放臂的回避以及新物体识别测试中的辨别能力丧失,分别衡量CMS诱导的快感缺失、焦虑症和认知功能障碍效应。在两个实验中均观察到氯胺酮在蔗糖摄入量测试中具有持续的抗抑郁样效应,起效时间约为1周,比丙咪嗪更快,最佳剂量为10毫克/千克。亚急性和慢性氯胺酮治疗均完全逆转了CMS在高架十字迷宫和新物体识别测试中分别产生的焦虑症和认知功能障碍效应。在CMS模型中每日用氯胺酮治疗可产生持续的长期抗抑郁、抗焦虑和促认知作用。氯胺酮促认知作用的证明可能具有特殊的转化价值。